B

BioMark Diagnostics Inc
SWB:20B

Watchlist Manager
BioMark Diagnostics Inc
SWB:20B
Watchlist
Price: 0.238 EUR 19%
Market Cap: 21.6m EUR
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one 20B stock under the Base Case scenario is 0.004 EUR. Compared to the current market price of 0.238 EUR, BioMark Diagnostics Inc is Overvalued by 98%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

20B Relative Value
Base Case
0.004 EUR
Overvaluation 98%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

240.8
P/S
P/S
Price to Sales
240.8
vs History
15
vs Industry
5
Median 3Y
143.8
Median 5Y
137.6
Industry
2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-14
Median 5Y
-14.2
Industry
18.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-24.6
Median 5Y
-24.4
Industry
11
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-15
Median 5Y
-17.7
Industry
14
More Details
28
P/B
P/B
Price to Book Value
28
vs History
1
vs Industry
Median 3Y
-20.2
Median 5Y
-22.5
Industry
1.7
More Details
228
EV/S
EV/S
Enterprise Value to Sales
228
vs History
15
vs Industry
5
Median 3Y
145
Median 5Y
139.2
Industry
3.1
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
6.8
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-15.6
Median 5Y
-16
Industry
10.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-12.6
Median 5Y
-13.4
Industry
13.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-24.3
Median 5Y
-23.8
Industry
11.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-24.2
Median 5Y
-23.8
Industry
12.3
More Details
129.9
EV/IC
EV/IC
Enterprise Value to IC
129.9
vs History
20
vs Industry
3
Median 3Y
52.6
Median 5Y
52.6
Industry
1.6
More Details

Multiples Across Competitors

20B Competitors Multiples
BioMark Diagnostics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
BioMark Diagnostics Inc
SWB:20B
37.3m EUR 240.8 -21.7 -24.1 -18.5
UK
Eight Capital Partners PLC
F:ECS
633.6T EUR 0 0 0 0
US
GE Vernova LLC
NYSE:GEV
150.8B USD 0 0 0 0
US
China Industrial Group Inc
OTC:CIND
121B USD 351.6 4 020.7 3 417.4 3 537.2
NL
Nepi Rockcastle NV
JSE:NRP
87.3B Zac 0 0 0 0
US
Coupang Inc
F:788
42.5B EUR 1.5 125.4 34.2 56.2
CH
Galderma Group AG
SIX:GALD
35.3B CHF 0 0 0 0
US
CoreWeave Inc
NASDAQ:CRWV
35B USD 0 0 0 0
US
Reddit Inc
NYSE:RDDT
34.7B USD 18.2 99.5 116.6 123.6
US
Symbotic Inc
NASDAQ:SYM
31.7B USD 14.9 -2 003.7 -534 -313.9
ID
Amman Mineral Internasional Tbk PT
IDX:AMMN
468.9T IDR 39.4 -108.7 2 363.4 2 363.4
P/S Multiple
Revenue Growth P/S to Growth
CA
B
BioMark Diagnostics Inc
SWB:20B
Average P/S: 111.1
240.8
N/A N/A
UK
E
Eight Capital Partners PLC
F:ECS
Not Available N/A N/A
US
G
GE Vernova LLC
NYSE:GEV
Not Available
11%
N/A
US
C
China Industrial Group Inc
OTC:CIND
351.6
N/A N/A
NL
N
Nepi Rockcastle NV
JSE:NRP
Not Available
-3%
N/A
US
Coupang Inc
F:788
1.5
15%
0.1
CH
G
Galderma Group AG
SIX:GALD
Not Available
17%
N/A
US
C
CoreWeave Inc
NASDAQ:CRWV
Not Available N/A N/A
US
R
Reddit Inc
NYSE:RDDT
18.2
44%
0.4
US
Symbotic Inc
NASDAQ:SYM
14.9
25%
0.6
ID
Amman Mineral Internasional Tbk PT
IDX:AMMN
39.4
N/A N/A
P/E Multiple
Earnings Growth PEG
CA
B
BioMark Diagnostics Inc
SWB:20B
Average P/E: 1 415.2
Negative Multiple: -21.7 		N/A N/A
UK
E
Eight Capital Partners PLC
F:ECS
Not Available N/A N/A
US
G
GE Vernova LLC
NYSE:GEV
Not Available
49%
N/A
US
C
China Industrial Group Inc
OTC:CIND
4 020.7
N/A N/A
NL
N
Nepi Rockcastle NV
JSE:NRP
Not Available
-5%
N/A
US
Coupang Inc
F:788
125.4
128%
1
CH
G
Galderma Group AG
SIX:GALD
Not Available
84%
N/A
US
C
CoreWeave Inc
NASDAQ:CRWV
Not Available N/A N/A
US
R
Reddit Inc
NYSE:RDDT
99.5
N/A N/A
US
Symbotic Inc
NASDAQ:SYM
Negative Multiple: -2 003.7 N/A N/A
ID
Amman Mineral Internasional Tbk PT
IDX:AMMN
Negative Multiple: -108.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
B
BioMark Diagnostics Inc
SWB:20B
Average EV/EBITDA: 1 482.9
Negative Multiple: -24.1 		N/A N/A
UK
E
Eight Capital Partners PLC
F:ECS
Not Available N/A N/A
US
G
GE Vernova LLC
NYSE:GEV
Not Available
51%
N/A
US
C
China Industrial Group Inc
OTC:CIND
3 417.4
N/A N/A
NL
N
Nepi Rockcastle NV
JSE:NRP
Not Available
7%
N/A
US
Coupang Inc
F:788
34.2
57%
0.6
CH
G
Galderma Group AG
SIX:GALD
Not Available
26%
N/A
US
C
CoreWeave Inc
NASDAQ:CRWV
Not Available N/A N/A
US
R
Reddit Inc
NYSE:RDDT
116.6
N/A N/A
US
Symbotic Inc
NASDAQ:SYM
Negative Multiple: -534 N/A N/A
ID
Amman Mineral Internasional Tbk PT
IDX:AMMN
2 363.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
B
BioMark Diagnostics Inc
SWB:20B
Average EV/EBIT: 1 520.1
Negative Multiple: -18.5 		N/A N/A
UK
E
Eight Capital Partners PLC
F:ECS
Not Available N/A N/A
US
G
GE Vernova LLC
NYSE:GEV
Not Available
88%
N/A
US
C
China Industrial Group Inc
OTC:CIND
3 537.2
N/A N/A
NL
N
Nepi Rockcastle NV
JSE:NRP
Not Available
12%
N/A
US
Coupang Inc
F:788
56.2
79%
0.7
CH
G
Galderma Group AG
SIX:GALD
Not Available
38%
N/A
US
C
CoreWeave Inc
NASDAQ:CRWV
Not Available N/A N/A
US
R
Reddit Inc
NYSE:RDDT
123.6
N/A N/A
US
Symbotic Inc
NASDAQ:SYM
Negative Multiple: -313.9 N/A N/A
ID
Amman Mineral Internasional Tbk PT
IDX:AMMN
2 363.4
N/A N/A

See Also

Summary
20B intrinsic value, competitors valuation, and company profile.
DCF Valuation
20B stock valuation using Discount Cash Flow valuation method.
Relative Valuation
20B stock valuation using valuation multiples.
Wall Street Estimates
20B price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
20B stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 298,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.